Infliximab ELISA (mAb-based)
Enzyme immunoassay for the specific and quantitative determination of free Infliximab (Remicade®, Remsima®) in human serum and plasma.
The solid phase (MTP) is coated by a highly specific monoclonal antibody directed against Infliximab. Therefore any cross reactivity to the other therapeutical monoclonal antibodies is excluded.
Reference: IG-AB101
Barcode: 8682754930035
Legal Status: CE-Mark
Intended Use: This kit has been developed for the measurement of drug levels in research and diagnostic uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.
Assay Design:
Related Documents
Instructions for Use IG-AB101 696.68 KB
Material Safety Data Sheet (MSDS) IG-AB101 268.16 KB
Quality Control Certificates
Quality Control Certificate Lot: AB101-208 295.08 KB
Quality Control Certificate Lot: AB101-207 293.95 KB
Quality Control Certificate Lot: AB101-206 303.77 KB
Quality Control Certificate Lot: AB101-205 302.92 KB
Quality Control Certificate Lot: AB101-204 156.93 KB
Quality Control Certificate Lot: AB101-203 157.93 KB
Quality Control Certificate Lot: AB101-202 156.61 KB
Quality Control Certificate Lot: AB101-104 157.52 KB
Quality Control Certificate Lot: AB101-103 157.61 KB
Quality Control Certificate Lot: AB101-102 160.14 KB
Remicade® is a trademark of Janssen Biotech, Inc./Merck & Co.
Remsima® is a trademark of CellTrion Inc.
The Kit at a glance:
| Required Volume (µL) | 10 |
| Incubation Time (min) | 100 |
| Sample | Serum or Plasma |
| Package Size | 96 |
| Standard Range (ng/mL, 10x) | 0-1500 |
| Sensitivity (ng/mL) | 3 |
| Spike Recovery (%) | >95 |
| Shelf Life (years) | 2 |
Standard Curve:
